Brutalist Biotech

• NIH fires exec amid probe into wife’s role in $3.3M contract: report (1h)
• Kezar sees hepatitis hold lifted, hints at resurrecting lupus program (2h)
• Repare finds suitor for paused PKMYT1 inhibitor in current partner Debiopharm (5h)
• AstraZeneca’s AL amyloidosis drug fails to reduce mortality in phase 3 test (6h)
• GSK telegraphs 'very limited number' of job cuts amid R&D investment spree (19h)
• HHS terminates employees after Supreme Court allows reduction in force to proceed (21h)
• Sellas’ CDK9 inhibitor tied to 50% response rate in certain AML patients in phase 2 study (1d)
• Sino Biopharm buys Merck's PD-1xVEGF bispecific partner LaNova for up to $951M (1d)
• Hengrui’s GLP-1/GIP agonist reports 18% weight loss in phase 3 trial, readies China push (1d)
• Acumen taps JCR’s blood-brain barrier tech for $555M Alzheimer’s deal (1d)
• China biotechs ‘reshaping’ US biopharma as outlicensing deals rise 11%: Jefferies report (2d)
• Merck wades deeper into HIV PrEP waters dominated by Gilead with 2 new late-stage trials (2d)
• Research non-profit to acquire embattled Essa in Xoma Royalty-backed deal (2d)
• Takeda’s narcolepsy blockbuster hopeful secures double phase 3 wins, teeing up FDA filing (2d)
• AstraZeneca’s $1.3B bet on CinCor’s blood pressure med appears to pay off with phase 3 win (2d)
• Relmada terminates license agreement for troubled phase 3 depression asset (5d)
• Karyopharm lays off more workers as hunt for strategic alternatives turns up short (5d)
• Quest Diagnostics to carry Fujirebio’s FDA-cleared Alzheimer’s blood test (5d)
• ‘Weak’ evidence and an ‘unpleasant’ odor: FDA sheds light on drug refusal process (5d)
• FDA rejects Capricor’s DMD cell therapy, asks for more data (5d)

• 33 states pick up CMS program to pay for sickle cell gene therapies (1h)
• Cancer drugmaker LaNova to sell to China’s Sino Biopharm (1d)
• Hengrui, Kailera say dual-acting obesity shot succeeds in China study (1d)
• Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug (1d)
• AstraZeneca blood pressure drug succeeds in late-stage trial (2d)
• Private equity firms back PCI Pharma in strategic bet on drug production (2d)
• FDA rejects Ultragenyx gene therapy over manufacturing concerns (2d)
• Takeda to seek approval of new kind of narcolepsy drug after study data (2d)
• From data to decisions: How pharma can move faster without sacrificing trust (2d)
• Jazz names new CEO; Ultragenyx, Mereo shares slide on trial update (5d)
• With Verona deal, Merck wagers on strength of lung drug’s patents (5d)
• FDA turns back Capricor’s Duchenne cell therapy (5d)
• Soleno sales of new Prader-Willi drug rise faster than expected (5d)
• Moderna COVID vaccine gets full approval for children (6d)
• FDA, in policy shift, publishes some drug rejection letters (6d)
• AbbVie to pay $700M for trispecific drug from Ichnos Glenmark (6d)
• Renasant Bio, chasing drugs for ADPKD, raises $55M in seed funding (6d)
• Lilly gets FDA OK of modified dosing for Alzheimer’s drug (7d)
• Merck to buy Verona and its lung drug in $10B deal (7d)
• Gilead signs lenacapavir access deal; Arvinas CEO to step down (7d)

• PureTech CEO leaves just one week after longtime chair steps down (19m)
• RFK replaces two top aides at HHS, including chief of staff (21m)
• Prime Medicine CSO departs, reveals new funding; FDA lifts partial hold on Kezar drug (41m)
• Endpoints livestream: Drugs and biomanufacturing in space with Varda CSO Adrian Radocea (1h)
• #IAS25: Jeanne Marrazzo, NIAID director placed on leave, on 'biggest threats' to HIV medicine (1h)
• J&J's Stelara faces continued biosimilar competition, with Q2 revenue falling 43% (3h)
• AstraZeneca says amyloidosis drug anselamimab failed in Phase 3 trials (4h)
• Debiopharm licenses Repare’s first-in-class cancer drug for $10M upfront (4h)
• #IAS25: As PEPFAR funding gets congressional support, HIV leaders warn of regression for the field (5h)
• BMS warns against ‘indiscriminate use’ of renegotiations as CMS plans next drug price talks (20h)
• About 2.5% of all drug patents cite government funding, new study finds (20h)
• GenBioPro loses bid to overturn West Virginia anti-abortion law (21h)
• Prasad overrode FDA vaccine reviewers on Moderna's Covid shot for young kids (21h)
• FDA questions the return of GSK's Blenrep in multiple myeloma ahead of adcomm (22h)
• Merck's partner LaNova Medicines is acquired for $951M by Sino Biopharmaceutical (1d)
• Labcorp drums up competition for health testing startups (1d)
• Otsuka buys immunology drugs; JCR, Acumen team up on Alzheimer’s program (1d)
• The Trump administration disbanded a federal newborn screening panel. Advocates now face a harder path (1d)
• Hengrui plans China filing for obesity shot following pivotal success (1d)
• FDA employees let go in April receive final termination notices (1d)

• AstraZeneca’s Amyloidosis Asset Stumbles in Late-Stage Trials (28m)
• J&J Raises 2025 Outlook as Oncology and Neuroscience Drive Q2 Growth (2h)
• GSK’s Blenrep DREAMMs Turn Fitful as FDA Questions Comeback in Multiple Myeloma (2h)
• Merck, AstraZeneca Cancer Collaborator Gets Swallowed Up by Sino Biopharm (2h)
• Vinay Prasad Overruled Reviewers on Moderna’s COVID-19 Shot for Kids (3h)
• FDA Layoffs, 200 Rejection Letters, User Fees and Priority Vouchers, Bad Week for Rare Disease (4h)
• When Feedback Feels Off: Using Critique That Doesn’t Feel Fair (5h)
• Audrey Greenberg: Out to Change the World, From Housing to Healthcare (10h)
• AI-Focused Biotech Unicorns Face Chilly Market Where IPOs Aren’t Guaranteed (11h)
• 5 Women Biotech Leaders Bagging Billions in M&A Dollars (11h)
• Bonus Episode: Q1 2025 Job Market Update (1d)
• HHS Begins Formally Laying Off Employees (1d)
• Gilead, GSK/ViiV, Merck Present New HIV PrEP Frontiers at IAS25 (1d)
• FDA Commissioner Marty Makary Proposes Lowering Industry User Fees (1d)
• Hengrui’s Dual GLP-1/GIP Elicits 17.7% Weight Loss in Phase III (1d)
• Acadia Debuts New Team, Pipeline With ‘Biotech Powerhouse’ Ambitions (1d)
• The Gap Between Administration’s Pro-Innovation Words and Policy (2d)
• AstraZeneca’s Baxdrostat Pushes Blood Pressure Lower in Phase III Trial (2d)
• Massachusetts-Based Karyopharm, Azurity Cut Workforces (2d)
• Takeda Establishes Lead in Narcolepsy Race With Back-to-Back Phase III Wins (2d)

Bio IT World

• A Popular Alzheimer’s Biomarker Found at High Levels in Newborns (10h)
• Pharma Companies Finding Their Way with AI (1d)
• Trends from the Trenches: What a TV Scientist Knows About Teaching Science (6d)
• From Physics to Longevity: How Gero’s ProtoBind-Diff Tool Reads Nature’s Hidden Drug Library (1w)
• Population Genomics Projects Around the World Gaining Ground (1w)
• Virtual Cell Challenge Announces Prize for AI Models of Cellular Response (2w)
• Anne Wojcicki Buys Back 23andMe for $305M, Promises Data Security (2w)
• Real-Time Drug Monitoring: A New Era for Drug Discovery and Development (2w)
• UK Study Demonstrates Real-World Value of Genetic Testing for Drug Prescribing (3w)
• Follow the Money: ITM’s Gastroenteropancreatic Therapy, GRIN, Angelini Pharma Collaborates, More (3w)
• Pangaea Data, Alexion Collaboration, Dell to Develop Supercomputer, More (3w)
• Nanoneedle Patch Enables Non-Invasive Tissue Sampling Offering Spatiotemporal Insights (4w)
• Black Swan Initiative: Multi-Pronged Research Strategy Targets Multiple Myeloma Cure (4w)
• Pistoia Alliance’s FAIR Maturity Assessment Tool (4w)
• Veteran ‘Lord of the Flies’ Takes a Crack at Addiction (1mo)
• NVIDIA, Novo Nordisk Collaborate to Bring AI Agents to Drug Discovery (1mo)
• A Farewell to Stan Gloss: Leading with Generosity and Other Words of Wisdom (1mo)
• MIT Researchers Unveil Boltz-2: AI Model Predicts Protein Structure, Binding Affinity in Seconds (1mo)
• Smart Bandage Merges Sensor Technology, Microfluidics, and AI (1mo)
• A Practical Precision Medicine Approach to Complex Chronic Diseases (1mo)

• Protein structure competition, of AlphaFold fame, nearing deal to replace lost NIH funding (34m)
• An unusual use for AI in medical education (1h)
• FDA questions safety of GSK’s multiple myeloma drug (1h)
• International consortium uncovers protein changes linked to neurodegenerative disease (1h)
• We’re reading about Trump and pharma tariffs, an abortion pill ruling, and more (2h)
• Medicare proposes ‘efficiency’ pay cuts that would hit highly paid specialists the most (6h)
• Oncologists need to see antimicrobial resistance as a cancer care delivery crisis (6h)
• Medical school prerequisites should include microbiology (6h)
• ViiV expands licensing deal for its HIV drug in low-income countries (18h)
• Federal judge reverses rule that would have removed medical debt from credit reports (20h)
• A troubled Sun Pharma plant fails yet another FDA inspection (23h)
• RFK Jr. gives vaccine skeptics plum HHS posts (1d)
• Kailera drug shows notable weight loss in China trial (1d)
• We’re reading about FDA user fees, rising GLP-1 use by children, and lots more (1d)
• The FDA approved another natural food dye (1d)
• HHS efficiency review blamed for delaying patient care at Indian Health Service (1d)
• A well-placed biotech investor says U.S. policies are straining life sciences startups (1d)
• The end of animal testing? Transitioning to models is promising — but no silver bullet (1d)
• I worked for 20 years for the HHS office that safeguarded people in research studies. DOGE gutted it (1d)
• Study finds no evidence aluminum salts in vaccines are tied to higher risk of asthma, other childhood diseases (1d)

• Google Expands MedGemma Collection With Multimodal Health AI Models for Open Development (6d)
• Xaira Therapeutics Appoints Biotech Exec Behind Belharra and Ambys as President and COO to Scale AI-Driven Drug Discovery Platform (7d)
• NIH To End Funding for Animal-Only Studies, Backing Shift to New Approach Methodologies (1w)
• datma Launches Free Tool for Pharma to Assess Biomarker Coverage in Federated RWD (1w)
• AbbVie Acquires Capstan Therapeutics for $2.1B, Gaining In Vivo CAR-T Platform Targeting Autoimmune Diseases (2w)
• Chai Discovery Releases All-Atom Foundation Model for Zero-Shot Antibody Design with 16–20% Hit Rates (2w)
• Into the Unknown — How Artificial Intelligence Can Help Biotech Companies Chart the Dark Genome (2w)
• Arc Institute Opens Virtual Cell Challenge With $175K in AI Benchmarking Prizes (3w)
• SandboxAQ Releases Public Database Containing 5.2 Million Synthetic Protein-Ligand Structures (3w)
• DeepMind Introduces New AI Tool for Predicting Effects of Human DNA Variants (3w)
• XtalPi Secures $100M Upfront in Drug Discovery Deal with DoveTree, Eyes $10B+ in Milestones (3w)
• Arc Institute Releases its First Virtual Cell Model (3w)
• NVIDIA Releases Agentic AI Blueprint for Literature Review and Target Discovery (4w)
• Nabla Raises $70M Series C to Expand Agentic AI Platform for Clinical Workflows (4w)
• Axiom Bio Releases Human Liver Toxicity Dataset with 130,000 Compounds to Advance AI-based Toxicity Prediction (4w)
• Xaira Publishes Largest Public Perturb-seq Atlas to Advance Virtual Cell Modeling (4w)
• Agenus and Noetik Partner to Develop AI-Based Biomarkers Using Virtual Cell Models (4w)
• Isomorphic Labs Appoints Ben Wolf as Chief Medical Officer, Expands to U.S. Hub in Cambridge (4w)
• Ryght AI Raises $3M to Automate Clinical Trial Site Activation with Agentic AI (4w)
• AstraZeneca Signs $5.3B AI Drug Discovery Deal with CSPC for Chronic Disease Programs (4w)

• Eight rare autoimmune diseases biotechs are fighting to treat (2h)
• Serial acquirer Concentra Biosciences on a buyout spree in 2025 (1d)
• Top biotech books of all time (2d)
• XOMA Royalty’s acquisition of Turnstone Biologics: what do royalty deals offer the biopharma industry? (5d)
• How OMass Therapeutics is tackling congenital adrenal hyperplasia, a rare genetic disorder (5d)
• Radiopharma’s new wave: Nuclidium and Actithera raise the stakes (6d)
• New hope for CIPN: Can emerging therapies ease chemotherapy’s nerve damage? (1w)
• The biggest biotech funding rounds in June 2025 (1w)
• Biotech in Vienna: a budding life science hub (1w)
• 14 biotech companies to know in the Boston area in 2025 (2w)
• Persica Pharmaceuticals is treating the cause of chronic lower back pain, not just the symptoms (2w)
• Revolutionizing glioblastoma treatment: How CAR-T cell therapy could represent a cure for this deadly brain cancer (2w)
• Top biotech deals in June 2025 (2w)
• Is an HIV cure possible? The future of HIV therapy (2w)
• Life sciences in Wales: biotechs in the scene in 2025 (2w)
• Psychedelics sans side effects: neuroplastogens gain ground (3w)
• Humacyte: Saving lives with lab-grown blood vessels in conflict zones (3w)
• How can treatment strategies evolve to address the challenges in chronic lymphocytic leukemia? (3w)
• ALS: how close are we to a cure? (3w)
• Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem (3w)

• New Voltage Sensing Technology Images Brain Activity to Understand Disease (17m)
• NIST Releases Pancreatic Cancer Panacea of Genomic Content (3h)
• NIST Releases Entire Genetic Content of Pancreatic Cancer Cell Analyzed Using Multiple Technologies (3h)
• AbbVie Licenses IGI Myeloma Candidate ISB 2001 for Up to $1.9B+ (16h)
• Global Neurodegeneration Proteomics Consortium Uncovers Biomarkers and Mechanisms (1d)
• Rapid Pathogen Detection in Low-Resource Settings Using Open-Source RT-LAMP Assay (1d)
• Feline Fever: Cell Therapy in Cats Sheds Clues on Long COVID (1d)
• $17.5B Deal Combines Waters with BD’s Biosciences and Diagnostics Business (1d)
• Recent NAM Guidelines Provide Much-Needed Step toward a More Productive Biotech Industry (1d)
• Elegen and Nutcracker Pilot Cell-Free Manufacturing Process for RNA-Based Personalized Cancer Therapeutics (1d)
• Catch a Fraudulent Scientist If You Can (2d)
• Consortium Aims to Deliver Fully-automated Robotics CGT Manufacturing Platform (2d)
• Novel Optogenetics Drug Discovery Screening Platform Identifies Antivirals (2d)
• Synaptic Plasticity Regulated by Protein Modifications Offer Path for Brain Therapeutics (2d)
• Many More Misfolded Proteins May Contribute to Alzheimer’s and Dementia than Previously Identified (3d)
• Repligen and Univercells Partner to Enable Real-Time Viral Vector and Vaccine Biomanufacturing Monitoring (3d)
• Biomanufacturing Industry to Face a ”Talent Singularity” in 2028 (4d)
• Why We Still Need Animal Research in a World of AI and Organoids (5d)
• Merck Acquires Verona, Virtual Cell Challenge, Gene Therapy Restores Hearing (5d)
• Ofichem Acquires Avivia to Expand Formulation Development Capabilities (5d)

• How Outpatient CAR T-Cell Therapy May Be Safer For Patients (2h)
• How Love Helped Me Face Leukemia and Keep Living (18h)
• How Biomarker Testing Can Inform Metastatic Breast Cancer Care (19h)
• Coping With a Rare Cancer Diagnosis, Like GIST (20h)
• Refining Treatment Approaches and Advancements in High-Risk Melanoma (22h)
• Celebrating My Clean Bill of Health After Cancer (23h)
• Bria-IMT Improves Survival in Patients With Metastatic Breast Cancer (1d)
• Evaluation and Diagnosis of Multiple Myeloma (1d)
• Introduction and Overview of Multiple Myeloma (1d)
• How ADCs Are Redefining Chemotherapy in Breast Cancer Care (1d)
• Finding Freedom and Uncertainty in My Cancer Remission Pause (1d)
• Understanding Novel Therapy Utility in HER2+ Breast Cancer Treatment (1d)
• Monjuvi Combo Reduces Progression Risk in Follicular Lymphoma (1d)
• The Power of Suggestion in Breast Cancer Prevention (2d)
• The Evolution of Survivorship After a Lung Cancer Diagnosis (2d)
• Real-World Data Supports Amtagvi’s Benefit in Advanced Melanoma (2d)
• Second Opinions Key for Those Newly Diagnosed With GIST (2d)
• Finding Comfort and Connection in the Chemo Lounge (2d)
• Meaningful Changes to Reduce Environmental Toxicities (3d)
• Understanding the Science Behind the Monjuvi Approval in Lymphoma (3d)

Contract Pharma*

• Tobin Scientific Opens New cGMP Warehouse in Wilmington, MA (57m)
• Satellos Appoints Wildon Farwell as Chief Medical Officer (1h)
• LogiCare3PL Partners with ChiRhoClin (1h)
• FDA Accepts Biologics License for Proposed Biosimilar to Simponi (2h)
• Thermo Fisher Scientific, Sanofi Expand Strategic Partnership (2h)
• Zhaoke Ophthalmology, Fareva Sign Memorandum of Agreement (23h)
• IL Group Introduces Light Protect Pack (23h)
• Evestia Clinical Merges with Atlantic Research Group (1d)
• 365mc, Raziel Therapeutics Partner to Jointly Advance RZL-012 in South Korea (1d)
• Antares Vision Group, LedgerDomain Partner to Streamline Supply Chain Security (1d)
• MilliporeSigma Introduces Automated Assay Workstation (1d)
• AATec Medical & Northway Biotech Develop ATL-105 (1d)
• Gil Roth - The Medicine Maker (1d)
• Uniquity Bio Appoints Will Kane President and CEO (2d)
• PCI Pharma Services Receives Strategic Investment from Bain Capital, Kohlberg and Mubadala (2d)
• Boehringer Ingelheim, LEO Pharma Partner to Commercialize & Develop SPEVIGO (2d)
• Cellular Origins, CGT Catapult, Resolution Therapeutics Partner for Automated Cell Therapy (5d)
• AbbVie & IGI Enter Global Licensing Agreement for Trispecific Antibody (5d)
• Flamma Opens New cGMP Plant in Dalian, China (5d)
• Gilead & Global Fund Partner for HIV Prevention (6d)

• North East NHS launches digital platform to tackle chronic kidney disease (2h)
• Proximie and HistoSonics partner to transform liver tumour treatment in US (2h)
• NHS England secures access to new cystic fibrosis treatment ALYFTREK (1d)
• MHRA approves first oral treatment for hereditary angioedema attacks (1d)
• Pierre Fabre secures China approval for BRAFTOVI combination in colorectal cancer (2d)
• Imperial study reveals DNA structure that could reverse ovarian cancer resistance (2d)
• Government to adopt EU standards for high-risk diagnostic devices (6d)
• Osivax publishes phase 2a results supporting dual flu vaccine approach (6d)
• BiomX phage therapy shows potent effect in cystic fibrosis trial (1w)
• Actithera closes $75.5m Series A to advance radioligand therapy platform (1w)
• VarmX secures US approval to begin phase 3 trial of urgent surgery treatment (1w)
• Clinical Researcher of the Year – The Americas (1w)
• First patient dosed in trial for novel dry AMD treatment PST-611 (1w)
• Eladynos recommended for osteoporosis treatment in Scottish NHS (1w)
• First German haemophilia B patient receives gene therapy HEMGENIX (2w)
• Neumifil shows promise in treating influenza with positive phase 2 dat (2w)
• Moderna flu vaccine shows superior results in phase 3 study (2w)
• UCB reports success in phase 3 study of fenfluramine for CDD (2w)
• Cidara and hVIVO report positive results in flu prevention study (2w)
• NHS ConfedExpo 2025: A platform for change in UK health and care (3w)

• The Crisis That Unites Us: Healthcare Costs Are Breaking Everyone (1h)
• Men’s Health is an Overlooked Part of Family Health: Why Employers Should Rethink Their Benefits Strategy (2h)
• Using Case Management to Improve Maternal Health Outcomes (3h)
• Report: Majority of Medicare Advantage Markets Lack Competition (16h)
• How Allina Health Is Modernizing Its Supply Chain Strategy (18h)
• Hengrui Pharma’s Potential Rival to El Lilly’s Zepbound Leads to 18% Weight Loss in Key Study (21h)
• No More Band-Aids: Hiring Isn’t the Answer to Burnout (1d)
• Generation Generative: What Healthcare Marketers Need To Know About Generative AI (1d)
• The Definitive Guide to Medical Billing Outsourcing: 5 Top Companies (1d)
• Why Hospitals Are Losing the Financial Tug-of-War With Payers (1d)
• New Bipartisan Bill from Rep. Carter Aims to Crack Down on PBMs (1d)
• Bayer’s Blockbuster Hopeful Kerendia Expands its FDA Approval to Type of Heart Failure (1d)
• Behavioral Health Has A Data Problem. Health Plans Are Sitting On The Solution (2d)
• Is Your Practice’s Payment System Holding You Back? Ask These 3 Key Questions (2d)
• From Plateau to Progress: Unleashing Growth in GI Practices Through Innovation and Alignment (2d)
• Are There Any Healthcare Wins Hidden Inside the One Big Beautiful Bill Act? Yes, a Few… (2d)
• Pledging ‘Radical Transparency,’ FDA Reveals Drug Rejection Letters — With Limits (2d)
• Women’s Health Company Tia Health Launches Longevity Service Line (3d)
• Better Navigation is Key to Improving Behavioral Health Access and Outcomes (3d)
• Healthcare’s Tariff Conundrum: Mitigating Supply Chain Risks with Data and Relationships (3d)

• How to successfully work with difficult people (3h)
• Waters to acquire BD flow cytometry business in a deal valued at $17.5 billion (19h)
• AI tool uses team approach to solve quantum chemistry problems (1d)
• ‘We have committed ourselves to this toxicity’ (1d)
• Team USA brings home gold at 57th International Chemistry Olympiad (2d)
• Chemistry in Pictures: That’s no moon (2d)
• US invests in rare earth firm MP Materials (4d)
• Protein sequences decoded from extremely old mammal teeth (4d)
• Atom-swapped morphine may help create safer painkillers (4d)
• Chemistry merit badge gets a new formula (4d)
• Gold Hydrogen raises funds for geological hydrogen (5d)
• Meet the 2025 CAS Future Leaders (5d)
• Skeletal editing: How close are we to true cut-and-paste chemistry? (5d)
• Microsoft AI predicts protein conformations (5d)
• The time I ate breakfast with a Nobel laureate (5d)
• Cancer drug Keytruda maker Merck buys Verona before patent cliff (5d)
• Climeworks raises $162 million to boost carbon capture from air (6d)
• Activist investors target Japan’s chemical giants (6d)
• Start-ups capture carbon dioxide in New York City (6d)
• Renasant Bio launches to develop kidney disease treatment (6d)

The Pharma Letter*

• Lilly’s $1 billion CRISPR bet: what Verve means for gene editing (1h)
• PureTech CEO Bharatt Chowrira steps down (2h)
• Number of patent disputes continue to grow in Russian pharma market (2h)
• Amvuttra gains UK approval for heart form of ATTR amyloidosis (2h)
• Phase III trial miss for AstraZeneca’s anselamimab (3h)
• ABPI says UK life sciences strategy at risk without medicines investment (4h)
• JCR Pharma links up with Acumen on Alzheimer’s research (4h)
• Medicaid to offer outcomes-based deal for sickle cell gene therapies (4h)
• Demands to thwart RFK Jr's “systematic assault” on global vaccination (5h)
• Sino Biopharm takes full ownership of LaNova in $951 million deal (5h)
• FDA approves Biocon BLA for Kirsty (5h)
• How tech transfer timelines can make or break an oral drug launch (21h)
• ICER assesses tolebrutinib’s worth in SPMS (21h)
• Hengrui and Kailera ready to file for approval of obesity candidate on positive Phase III trial (23h)
• Russia to begin commercial production of new anticancer vaccine (1d)
• ViiV's HIV portfolio delivering on different fronts (1d)
• Hidden cost of 340B: a multi-billion-dollar burden on taxpayers and Medicaid (1d)
• MHRA approves Ekterly to treat HAE (1d)
• New RayzeBio hub promises to deliver radiopharmaceutical therapies in three days (1d)
• Tract Bio adds CMO and board members as stem cell pipeline advances (1d)

• Across Cancer Types, Trispecific Antibodies Show Promise in Early Result (18m)
• Dual Bispecific Therapy Shows Promise in High-Risk Multiple Myeloma With EMD (1h)
• Addressing Financial Toxicity and Food Insecurity in Cancer Care (2h)
• Awareness of TIL Therapy for Melanoma Is Crucial for Timely Referral (20h)
• Medina on Patient Selection for Lifileucel in Melanoma (21h)
• Targeted Brain Radiation Yields Promising Outcomes in SCLC Brain Metastases (22h)
• Stereotactic Radiation: New Standard for Brain Metastases (23h)
• Immunotherapy Duo Shows 42% 2-Year Survival in MSS CRC Trial (1d)
• FDA Grants Orphan Drug Designation to SH-110, a Liquid Glioma Therapy (1d)
• PROGRxN-BCa AI Model Shows Broad Accuracy in NMIBC Prediction (1d)
• Tabelecleucel Advances in EBV+ PTLD With Phase 3 Trial and FDA Resubmission (1d)
• Dr Weiss Reviews Key Melanoma Updates From ASCO 2025 (1d)
• Recent Clinical Advances: Key Trial Data in First-Line mTNBC (1d)
• Current First-Line Treatment Landscape for mTNBC (1d)
• Evaluating Efficacy of Second-Line RCC Treatments Post-Immunotherapy (1d)
• Affected Organs and Availability Influence Choice of cGVHD Therapy (1d)
• NDA for Relacorilant in Platinum-Resistant Ovarian Cancer Submitted to FDA (1d)
• SRT Radiation Shows Superiority Over WBRT for Brain Metastases (1d)
• FDA's Oncologic Drugs Advisory Committee Casts Interesting Votes (2d)
• RAMP 201 Data Shows Advancements in Recurrent Low-Grade Serous Ovarian Cancer (2d)

• Lawsuits rain down on Hims & Hers after Novo Nordisk partnership ends (2h)
• Johnson & Johnson surprises with higher Darzalex sales – share price rises (4h)
• EU Commission makes final verdict in price cartel case (4h)
• The FDA approves another Novolog copy (6h)
• Investor on Leo Pharma's new acquisition: "It's not like the market is thinking wow" (7h)
• Convatec sees risk of Medicare proposal hitting patients (1d)
• Coloplast welcomes US' extensive cost-saving on wound care (1d)
• Coloplast and rivals fall on stock exchange: Medicare to limit skin and wound care spending (1d)
• EU countries support robust response to Trump if tariff deal fails (1d)
• China biotech’s stunning advance is changing the world’s drug pipeline (1d)
• Tylenol-maker Kenvue appoints interim CEO (2d)
• US Administration's price plans for big pharma will lead to fighting (2d)
• Leo Pharma signs multi-million-euro deal with Boehringer Ingelheim: Acquires rights to psoriasis drug (2d)
• EU considers new counter-tariffs to ensure fair deal with the US (2d)
• AstraZeneca rewarded on the stock exchange after strong data with blood pressure drug (2d)
• EMA lifts restrictions on Valneva’s chikungunya vaccine (2d)
• Company raises hefty sum to boost production of medicines in space (2d)
• GN Store Nord is Denmark's most shorted stock (5d)
• AbbVie invests USD 700m in investigational asset through new licensing deal (5d)
• Orifarm enters Spain - announces new country manager (5d)

• Dual Antibody Conjugates For Twice the Excitement (17h)
• Sulfonate Esters in Drug Substances: Real Problem or Not? (1d)
• Senolytic Update (5d)
• Hexanitrogen Energies (6d)
• Thinking About Covalent Drug Reactivity (1w)
• Tell the Bot to Tell the Bot About the Bot (1w)
• The Fourth Of July, 2025 (2w)
• New Assays Are Always Welcome (2w)
• Down In the Reaction Details (2w)
• The "Healthy Vaccinee" Effect (3w)
• The Continuing Crisis, Part XVI: Get the Hell Out of Your Building (3w)
• Tiny Crystals from Small Extracts (3w)
• Hexanitrogen (3w)
• Stir Bars Can't Be Ignored (4w)
• AI Effects on Drug Patents (4w)
• Mirror Morphine (1mo)
• Vaccine Advice, Vandalized (1mo)
• Novo Nordisk's Canadian Mistake (1mo)
• The Bethesda Declaration (1mo)
• Taurine and Aging: Is There Anything to It? (1mo)

• NHS trust rolls out digital health tool for kidney disease (2h)
• FDA fast-tracks Sanofi's gene therapy for eye disease GA (3h)
• AstraZeneca sifts for efficacy crumbs in amyloidosis trial (4h)
• MSD, AZ partner LaNova bought by Sino Biopharm for $951m (6h)
• HHS layoffs are finalised as thousands of pink slips arrive (7h)
• Hengrui to file obesity shot in China after phase 3 win (1d)
• LEO bulks up with deal for Boehringer skin drug (1d)
• Gilead's twice-yearly HIV PrEP set for wider rollout (1d)
• UK Biobank charts success of NHS imaging project (1d)
• New cystic fibrosis triple from Vertex backed for NHS use (1d)
• UK project addresses capacity issue in CGT manufacturing (2d)
• Takeda's narcolepsy programme gets back on track (2d)
• AZ prepares to file blood pressure drug after trial win (2d)
• Bayer gets sought-after heart failure use for Kerendia (2d)
• Paper gives hint of Apple's thinking on AI and health (2d)
• Case builds for Biogen, Stoke's Dravet syndrome drug (5d)
• AbbVie cuts $1.9bn+ deal with IGI for trispecific antibody (5d)
• Bayer bags first world approval for hot flush therapy (5d)
• Cash injection will help Varda make drugs in space (5d)
• Just how radical is the FDA's complete response letter move? (5d)

• Guide: 10 practical tips for reliable MEA experiments in preclinical neuroscience (1h)
• Webinar: The strategic power of pathology and AI for biopharma RD (3h)
• 10 practical tips for reliable MEA experiments in preclinical neuroscience (4h)
• From the Editor: Not NICE enough (5h)
• New optogenetic screening platform for drug discovery (6h)
• Rewiring drug development: The strategic power of pathology and AI for biopharma RD (6h)
• Partnership to scale cell-based mRNA platform (6h)
• SLC7A11 inhibitors could remove skin cancer’s protective armour (23h)
• FUJIFILM’s biliary tract cancer drug granted FDA orphan status (1d)
• Mezagitamab and the future of ITP treatment (1d)
• JCR and Alexion deal boosts AAV-based gene therapy (1d)
• EU go-ahead for nasopharyngeal carcinoma drug (1d)
• US company hopes to transform access to advanced biologics (1d)
• Industry insights from Q2 2025 events (2d)
• New DDW Highlights podcast: 14 July 2025 (2d)
• DDW Highlights: 14 July 2025 (2d)
• Atsena expedites gene therapy for X-linked retinoschisis (2d)
• Cancer Research Horizons rewards innovation and entrepreneurship (2d)
• AbbVie licenses trispecific antibody in billion-dollar contract (2d)
• Biotech raises capital for new oral obesity treatment (2d)

Google News Biotech

• MEPs signal backing for public-private deals amid biotech report rewrite - Euractiv (19m)
• Generation Bio Surges 17% Amid Biotech Breakthrough Buzz – What’s Next? - AInvest (44m)
• China's domestic biotech industry is becoming a global force - China Daily - Global Edition (1h)
• Biotech company licenses new microbiome-sparing antibiotic developed at Illinois - Carle Illinois College of Medicine (1h)
• Lilly’s $1 billion CRISPR bet: what Verve means for gene editing (1h)
• FDA questions safety of GSK’s multiple myeloma drug - STAT (1h)
• China's domestic biotech industry is becoming a global force - China Daily (1h)
• Oncolytics Biotech Unveils Promising Data on Pelareorep’s Efficacy Across Tumor Types - TipRanks (2h)
• Legend Biotech Reports Strong Sales for CARVYKTI® in Q2 2025 - TipRanks (2h)
• Korean Biotech Startup Targeting Alzheimer’s Treatment Raises $42 Million Round - Forbes (2h)
• Oncolytics Biotech reports positive biomarker data for pelareorep By Investing.com - Investing.com India (2h)
• Oncolytics Biotech reports positive biomarker data for pelareorep By Investing.com - Investing.com Nigeria (2h)
• How this $40M biotech facility will give bourbon distillery byproduct a new life - The Courier-Journal (2h)
• IO Biotech, Inc.'s (NASDAQ:IOBT) largest shareholders are private equity firms who were rewarded as market cap surged US$16m last week - simplywall.st (2h)
• Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types - Morningstar (2h)
• Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types - Yahoo Finance (2h)
• Lilly’s Zepbound faces a potential weight-loss rival. It’s made by a Chinese biotech - Mint (3h)
• LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements - GlobeNewswire (3h)
• LIXTE Secures $6.5M Funding, Maintains Nasdaq Listing While Advancing Cancer Drug Trials - Stock Titan (3h)
• Legend Biotech Reports Strong CARVYKTI® Sales for Q2 2025 - TipRanks (3h)